CI · Cigna Group
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 30, 2026TL;DR. Cigna reported Q2 2026 adjusted EPS of $7.78 on $71.7B in revenues and raised full-year 2026 adjusted EPS guidance to at least $30.45, while Cigna Healthcare pre-tax adjusted earnings grew 17% but Pharmacy Benefit Services pre-tax adjusted earnings fell 27% year-over-year amid GLP-1 moderation and a higher 84.5% MCR.
- + Raised full-year 2026 adjusted EPS outlook to at least $30.45 from prior guidance.
- + Cigna Healthcare pre-tax adjusted earnings grew 17% year-over-year on improved U.S. Employer margins.
- + Raised full-year Cigna Healthcare pre-tax adjusted earnings outlook to at least $4.55 billion.
- + Strong 2027 PBM selling season with new business secured exceeding prior selling seasons combined.
- − Pharmacy Benefit Services pre-tax adjusted earnings fell 27% year-over-year to $609 million on large client renewals and Signature transition investments.
- − Moderating GLP-1 growth produced a modest headwind to PBS and 2026 Evernorth results.
- − Planned exit from Individual and Family Plans business on January 1, 2027, with stranded overhead expected in 2027.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CI
this stock
Cigna Group
|
$75.22B | +0.0% | +11.2% | 11.8 | 2.4% |
|
UNH
Unitedhealth Group Inc
|
$338.37B | +14.2% | +11.8% | — | 1.7% |
|
CVS
CVS HEALTH Corp
|
$118.77B | +11.9% | +7.8% | 24.5 | 1.4% |
|
ELV
Elevance Health, Inc.
|
$90.52B | +17.2% | +12.5% | 18.5 | 2.5% |
|
HUM
Humana Inc
|
$46.17B | +50.8% | +10.1% | 41.0 | 2.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CI | -2.0% | +0.3% | +5.1% | -0.3% | +0.0% |
| SPY | -0.3% | -0.1% | +20.1% | -0.7% | +11.7% |
| vs SPY | -1.6% | +0.4% | -15.0% | +0.4% | -11.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.